A PAK1 Mutational Hotspot Within the Regulatory CRIPaK Domain is Associated With Severe Neurodevelopmental Disorders in Children.


Journal

Pediatric neurology
ISSN: 1873-5150
Titre abrégé: Pediatr Neurol
Pays: United States
ID NLM: 8508183

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 07 11 2022
revised: 01 09 2023
accepted: 12 09 2023
medline: 27 11 2023
pubmed: 12 10 2023
entrez: 11 10 2023
Statut: ppublish

Résumé

P-21-activated kinases (PAKs) are protein serine/threonine kinases, part of the RAS/mitogen-activated protein kinase pathway. PAK1 is highly expressed in the central nervous system and crucially involved in neuronal migration and brain developmental processes. Recently, de novo heterozygous missense variants in PAK1 have been identified as an ultrarare cause of pediatric neurodevelopmental disorders. We report a series of children affected with postnatal macrocephaly, neurodevelopmental impairment, and drug-resistant epilepsy. Repeated electroencephalographic (EEG) and video-EEG evaluations were performed over a two- to 10-year period during follow-up to delineate electroclinical histories. Genetic sequencing studies and computational evaluation of the identified variants were performed in our patient cohort. We identified by whole-exome sequencing three novel de novo variants in PAK1 (NM_001128620: c.427A>G, p.Met143Val; c.428T>C, p.Met143Thr; c.428T>A, p.Met143Lys) as the underlying cause of the disease in our families. The three variants affected the same highly conserved Met143 residue within the cysteine-rich inhibitor of PAK1 (CRIPaK) domain, which was identified before as a PAK1 inhibitor target. Computational studies suggested a defective autoinhibition presumably due to impaired PAK1 autoregulation as a result of the recurrent substitution. We delineated the electroclinical phenotypes of PAK1-related neurological disorders and highlight a novel mutational hotspot that may involve defective autoinhibition of the PAK1 protein. The three novel variants affecting the same hotspot residue within the CRIPaK domain highlight potentially impaired PAK1-CRIPaK interaction as a novel disease mechanism. These findings shed light on possible future treatments targeted at the CRIPaK domain, to modulate PAK1 activity and function.

Sections du résumé

BACKGROUND BACKGROUND
P-21-activated kinases (PAKs) are protein serine/threonine kinases, part of the RAS/mitogen-activated protein kinase pathway. PAK1 is highly expressed in the central nervous system and crucially involved in neuronal migration and brain developmental processes. Recently, de novo heterozygous missense variants in PAK1 have been identified as an ultrarare cause of pediatric neurodevelopmental disorders.
METHODS METHODS
We report a series of children affected with postnatal macrocephaly, neurodevelopmental impairment, and drug-resistant epilepsy. Repeated electroencephalographic (EEG) and video-EEG evaluations were performed over a two- to 10-year period during follow-up to delineate electroclinical histories. Genetic sequencing studies and computational evaluation of the identified variants were performed in our patient cohort.
RESULTS RESULTS
We identified by whole-exome sequencing three novel de novo variants in PAK1 (NM_001128620: c.427A>G, p.Met143Val; c.428T>C, p.Met143Thr; c.428T>A, p.Met143Lys) as the underlying cause of the disease in our families. The three variants affected the same highly conserved Met143 residue within the cysteine-rich inhibitor of PAK1 (CRIPaK) domain, which was identified before as a PAK1 inhibitor target. Computational studies suggested a defective autoinhibition presumably due to impaired PAK1 autoregulation as a result of the recurrent substitution.
CONCLUSIONS CONCLUSIONS
We delineated the electroclinical phenotypes of PAK1-related neurological disorders and highlight a novel mutational hotspot that may involve defective autoinhibition of the PAK1 protein. The three novel variants affecting the same hotspot residue within the CRIPaK domain highlight potentially impaired PAK1-CRIPaK interaction as a novel disease mechanism. These findings shed light on possible future treatments targeted at the CRIPaK domain, to modulate PAK1 activity and function.

Identifiants

pubmed: 37820543
pii: S0887-8994(23)00313-2
doi: 10.1016/j.pediatrneurol.2023.09.005
pii:
doi:

Substances chimiques

p21-Activated Kinases EC 2.7.11.1
Protein Serine-Threonine Kinases EC 2.7.11.1
PAK1 protein, human EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

84-92

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Auteurs

Giovanna Scorrano (G)

Department of Pediatrics, University of Chieti-Pescara, Chieti, Italy; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

Gianluca D'Onofrio (G)

Pediatric Neurology and Muscular Diseases Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genova, Italy; Unit of Medical Genetics, IRCCS Istituto Giannina Gaslini, Genova, Italy.

Andrea Accogli (A)

Department of Medical Genetics, Montreal Children's Hospital, McGill University Health Centre (MUHC), Montreal, QC, Canada; Department of Human Genetics, McGill University, Montreal, QC, Canada.

Mariasavina Severino (M)

Neuroradiology Unit, IRCCS Istituto "Giannina Gaslini", Genova, Italy.

Rebecca Buchert (R)

Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.

Urania Kotzaeridou (U)

Division of Child Neurology and Inherited Metabolic Diseases, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany.

Giulia Iapadre (G)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

Giovanni Farello (G)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

Michele Iacomino (M)

Unit of Medical Genetics, IRCCS Istituto "Giannina Gaslini", Genova, Italy.

Fedele Dono (F)

Department of Neuroscience, Imaging and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Chieti, Italy.

Ludovica Di Francesco (L)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

Maria Francesca Fiorile (MF)

Department of Pediatrics, University of Chieti-Pescara, Chieti, Italy.

Saverio La Bella (S)

Department of Pediatrics, University of Chieti-Pescara, Chieti, Italy.

Antonio Corsello (A)

Department of Clinical Science and Community Health, University of Milan, Milan, Italy.

Elisa Calì (E)

Department of Neuromuscular Disorders, UCL Queen Square Institute of Neurology, London, UK.

Gabriella Di Rosa (G)

Unit of Child Neurology and Psychiatry, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, Messina, Italy.

Eloisa Gitto (E)

Neonatal and Pediatric Intensive Care Unit, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, Messina, Italy.

Alberto Verrotti (A)

Department of Pediatrics, University of Perugia, Perugia, Italy.

Sara Fortuna (S)

Computational Modelling of Nanoscale and Biophysical Systems Laboratory (CONCEPT), Istituto Italiano di Tecnologia (IIT), Genova, Italy.

Miguel A Soler (MA)

Department of Mathematics, Computer Science and Physics, University of Udine, Udine, Italy.

Francesco Chiarelli (F)

Department of Pediatrics, University of Chieti-Pescara, Chieti, Italy.

Barbara Oehl-Jaschkowitz (B)

Bioscientia-MVZ-Labor-Saar-Praxis für Humangenetik, Homburg, Germany.

Tobias B Haack (TB)

Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.

Federico Zara (F)

Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genova, Italy; Unit of Medical Genetics, IRCCS Istituto Giannina Gaslini, Genova, Italy; Unit of Medical Genetics, IRCCS Istituto "Giannina Gaslini", Genova, Italy.

Pasquale Striano (P)

Pediatric Neurology and Muscular Diseases Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genova, Italy; Unit of Medical Genetics, IRCCS Istituto Giannina Gaslini, Genova, Italy.

Vincenzo Salpietro (V)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; Department of Neuromuscular Disorders, UCL Queen Square Institute of Neurology, London, UK. Electronic address: v.salpietro@ucl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH